Psoriasis and fatty liver: a harmful synergy

Area of Science:

• Dermatology
• Hepatology
• Immunology

Background:

• Psoriasis and non-alcoholic fatty liver disease (NAFLD) frequently co-occur, with epidemiological studies showing a significantly increased risk of NAFLD in severe psoriasis patients (OR 2.15).
• Both conditions exhibit a synergistic relationship, where each disease exacerbates the other's severity.
• Common pathogenic factors, including insulin resistance, metabolic syndrome, and a shared inflammatory cytokine profile, underlie this association.

Purpose of the Study:

• To highlight the increased prevalence and severity of NAFLD in patients with psoriasis.
• To elucidate the shared etiological pathways and inflammatory mechanisms connecting psoriasis and NAFLD.
• To emphasize the need for interdisciplinary collaboration between dermatologists and hepatologists for optimal patient management.

Main Methods:

• Review of epidemiological studies and clinical observations on the co-occurrence of psoriasis and NAFLD.
• Analysis of shared risk factors such as metabolic syndrome and insulin resistance.
• Examination of the role of cytokine-mediated inflammation in the pathogenesis of both diseases.

Main Results:

• Patients with psoriasis demonstrate a more severe liver disease, directly correlated with psoriasis severity.
• Conversely, patients with NAFLD often present with more severe psoriasis.
• The combined manifestation of psoriasis and NAFLD is more intense than either condition alone.

Conclusions:

• Dermatologists should screen patients with metabolic syndrome for liver disease, while hepatologists must recognize the heightened severity in patients with psoriasis.
• Hepatotoxic medications like acitretin, cyclosporine, and methotrexate should be used cautiously in these patients.
• Biologic therapies have shown safety in patients with co-existing chronic liver disease, and collaborative management is crucial to optimize therapy and avoid hepatotoxicity.